NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-50497

Glas, M; Bähr, O; Felsberg, J; Rasch, K; Wiewrodt, D; Schabet, M; Simon, M; Urbach, H; Steinbach, J P; Rieger, J; Fimmers, R; Bamberg, M; Nägele, T; Reifenberger, G; Weller, M; Herrlinger, U (2011). NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri. Annals of Neurology, 70(3):445-53.

Accepted Version
PDF - Registered users only
891Kb

Abstract

PC chemotherapy is effective in GC. With the NOA-05 trial being the first prospective multicenter trial in GC, PC chemotherapy can be regarded as a promising option for the primary therapy of these tumors.

Item Type:	Journal Article, refereed, original work
Communities & Collections:	04 Faculty of Medicine > University Hospital Zurich > Clinic for Neurology
DDC:	610 Medicine & health
Date:	2011
Deposited On:	03 Nov 2011 15:29
Last Modified:	26 Nov 2012 21:48
Publisher:	Wiley-Blackwell
ISSN:	0364-5134
Publisher DOI:	10.1002/ana.22478
PubMed ID:	21710625
WoS Citation Count:	2

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page